Percutaneous Vertebroplasty as a Treatment for Osteoporotic Vertebral Compression Fractures

Alimov Ijod* and Abdusattarov Khurshid

Department of Traumatology, Orthopedics, Military field Surgery and Neurosurgery, Uzbekistan

Submission: March 19, 2018; Published: April 11, 2018

*Corresponding author: Alimov Ijod, Department of Traumatology, Orthopedics, Military Field Surgery and Neurosurgery, Tashkent Medical Academy 100109, Tashkent, Farabi Street 2, Uzbekistan, Email: a.neurosurgery@bk.ru

Abstract

Percutaneous vertebroplasty is a minimally invasive procedure for the treatment of osteoporotic and neoplastic vertebral compression fractures; this procedure involves the injection of bone cement directly into the fractured vertebral body. The purpose of this study was to evaluate the efficacy of percutaneous vertebroplasty for patients with painful osteoporotic vertebral compression fractures. This was a retrospective single-center study; the total number 74 percutaneous vertebroplasty was performed in 41 patients with osteoporotic vertebral body compression fractures of the I and II degrees. Of these 41 patients, 5 were male (12%) and 36 (88%) were female; the average age of the patients was 66 years (range, 55-78 years). The overall procedure time was 51.2 ± 4.2 (range, 34-55) min. The average cement volume injected into vertebra was 4.5 ± 0.54 (range, 3.4-6.0) ml. The mean follow-up was 16.0 ± 4.2 (range, 12-24) months. All patients achieved substantial pain relief after surgery; the Visual Analogue Scale (VAS) score decreased significantly from a pre-operative value of 8.4 ± 1.2 to a post-operative value of 2.0 ± 0.2, and was maintained at 2.2 ± 0.4 at the final follow-up (p < 0.01). Our study confirmed that percutaneous vertebroplasty is an effective treatment modality for osteoporotic vertebral compression fractures, which offers short and long-term statistically significant benefits in decreasing pain and increasing mobility.

Keywords: Osteoporotic vertebral compression fractures; Percutaneous vertebroplasty

Introduction

Osteoporotic vertebral compression fractures (OVCFs) are the most common single osteoporotic fractures worldwide, constituting an integral part of the osteoporotic syndrome; they occur in 30-50% of people over the age of 50 [1]. The OVCFs have a negative impact on health related quality of life and are associated with increased mortality. Conservative management, including bed rest, pain relievers, bracing and physical therapy, may fail to relieve pain and frequently lead to prolonged immobilization, depression and a substantial negative impact on life quality. Percutaneous vertebroplasty (PVP) is a minimally invasive procedure for the treatment of OVCFs; it consists of percutaneous injection of biomaterial, such as Polymethyl methacrylate (PMMA), into the fractured vertebral body [2]. The procedure is well tolerated even under local anesthesia. Biomechanical testing has shown that PVP can restore strength and stiffness of the vertebral body to the pre-fracture levels. The advantages of PVP included are following: reduction in pain, disability, and analgesic use; as well as stabilization of the vertebral fracture [3]. The short-term risk factors of PVP are associated with a cement leakage into the spinal canal or into the venous system; the long-term risk factor of PVP is incidence of new vertebral fracture. The PVP as a treatment mode for painful vertebral compression fractures provided long-term therapeutic effects in 70-95% of the patients [4]. Cost-effectiveness analysis revealed that PVP is most cost-effective treatment procedure in patients with OVCFs in Japan [5]. Thus, the aim of our study was to evaluate the immediate post-interventional and long-term outcomes after PVP in terms of pain relief.

Material and Methods

Data were collected retrospectively from the records of patients treated between 2015 and 2017 at the department of “Traumatology, orthopedics, neurosurgery with military surgery” of the Tashkent Medical Academy (TMA). The study was executed in compliance with the Helsinki Declaration and local data protection regulations of TMA. The database included data from patients who signed an informed consent form allowing the use of their clinical data for research purposes. Indications for PVP were the presence of single or multiple vertebral compression fractures of vertebral bodies of the I and II degree with a strong pain syndrome, along with osteoporosis, which was preoperatively diagnosed by dual-energy X-ray absorptiometry (DXA). Patients undergoing vertebroplasty for other conditions such as vertebral metastasis, multiple myeloma or traumatic fractures of the spine were excluded. Contraindications of PVP
were following: osteomyelitis, discitis or active systemic infection; unstable spinal fracture, patients with diffuse idiopathic skeletal hyperostosis and ankylosing spondylitis; severe uncorrectable coagulopathy; impaired cardiopulmonary function; neurologic deficits and spinal cord compression syndrome; bone fragment retroulsion; allergy to bone cement or opacification agents. The following examinations were made in all the patients prior PVP: detailed clinical evaluation, including a the neurological status; blood test with extended coagulogram; imagining modalities such as such X-ray, magnetic resonance tomography (MRT) or multislice computed tomography (MSCT). Osteoporosis was preoperatively diagnosed by dual X-ray absorptiometry in all patients. In order to evaluate the severity of the pain, the visual analog scale (VAS) was used; this system grades pain based on the following: 0=absence of pain, 2 = mild pain, 4=moderate pain, 6=severe pain, 8=extreme pain 10=worst pain. The cemented proportion of the vertebral body was determined using volumetric analysis of the postoperative CT scan of the treated levels.

Statistical analysis was performed using SPSS for Windows version 18.0 (SPSS Inc., Chicago, IL, USA). All variables were analysed using descriptive statistical methods. Data are presented as the mean and standard deviation for continuous variables and as percentages for categorical variables. Comparisons of pain outcomes pre- and postoperatively were made using a paired t test. Differences were considered statistically significant when \( p < 0.05 \).

**Procedure**

The preoperative prophylactic antibiotic cefazolin 1g, was administered intravenously. The procedure was performed under local anesthesia. The transpedicular approach was used to access the collapsed vertebral body in the thoracic and lumbar spine. The vertebral venography has been used for the identification of potential routes of cement venous leakage. The cement is composed of methyl methacrylate and monomer liquid, which were mixed together. Cement injection was done under continuous lateral fluoroscopic control; it was injected using a 13-gauge cannula. The fractured vertebral body was gradually filled with cement until admissible endpoints. Cement injection was interrupted in case of venous leakage into the veins or spinal canal. Patients were in supine position within 1.5 hour after the procedure, the assessment of vital functions and neurological status were examined in every 15 minutes. The control MSCT or CT of the treated level was performed in the first 2-3 days after the procedure.

A total of 41 patients (36 females and 5 males) met the inclusion criteria and were treated with PVP and then included in the follow-up program that is still going on. The total number 74 percutaneous vertebroplasty was performed in 41 patients with traumatic compression fractures of vertebral bodies of the I and II degree. Of these 41, 5 participants were male (12%) and 36(88 %) were female; the average age of the patients was 66 years (range, 55-78 years). The average operative time was 51.2 ± 4.2 (range, 34-55)min. The average cement volume was 4.5 ± 0.54 (range, 3.4-6.0)ml. The mean follow-up was 16.0 ± 4.2 (range, 12-24) months. The evaluation of the results of treatment was carried out according to the following criteria: dynamics and severity of pain syndrome prior and after percutaneous vertebroplasty, motor activity of the patient, and dependence on analgesics. All patients achieved substantial pain relief after surgery. The VAS score decreased significantly from a preoperative value of 8.4 ± 1.2 to a post-operative value of 2.0 ± 0.2 and was maintained at 2.2 ± 0.4 at the final follow-up (p < 0.01). The extravasation of cement into the venous plexuses was noted in 1 patient, which was the reason of occlusion of small branches of the pulmonary arteries, and clinical presentations of this case was asymptomatic. No other complications were encountered. All patients were able to sustain rapid mobilization within 12-24h after procedure, and the mean hospitalization length after PVP was 3.5 days (range 3-5). The long-term results revealed that all patients had significantly improved mobility, and by the end of the first postoperative month and mainstay during following 24 month, there were not any subsequent vertebral fractures. In additionally, during the follow up period the majority of patients reported that decreased usage pain relief medicines or not used (Figure 1 & 2).

![Figure 1](image1.png) **Figure 1:** MRI, the T1-weighted sagittal image before surgery. The patient K. was 62 years old. There are signs of low-traumatic compression fracture of the body VL2 II degree.
 modifications of injected cements are being developed in experimental studies. Schroder et al. [9], conducted experimental study to examine the influence of adding 10 and 30 vol% isotonic saline on the biomechanical properties of PMMA vertebroplasty cement. The result of this study demonstrated that compressive stiffness of PMMA-based vertebroplasty cement could be reduced to almost a third by the addition of saline. The probable explanation is an increase in microporosity of cement, which can reduce the risk of subsequent vertebral fractures [9]. Another investigation by Liu et al. [10] tested newly designed CPB cement for replacing the PMMA in PVP and PKP. The biomechanical, biocompatibility, osseointegrative and handling properties of CPB were systematically evaluated in vitro and in vivo. The results of this investigation demonstrated that the biological performance of CPB outperformed the non-degradable PMMA. The authors concluded that CPB has revolutionary potential to replace the PMMA in the applications such as PVP and PKP [10]. Certainly, the above-mentioned two experimental studies are required further evaluation in clinical settings.

**Conclusion**

Our study demonstrated that PVP offers statistically significant short and long-term benefits in decreasing pain and increasing mobility for patients with OVCFs. The perioperative risk of cement leakage was observed only in one patient, there were not any subsequent vertebral fractures in long-term follow-up.

**References**
